Podxl in bladder cancer
AssigneeAtlas Antibodies AB
InventorKarin Jirstrom
Life of this patent
Estimating the term…
Abstract
There is provided a method for determining whether a mammalian subject having a bladder cancer belongs to a first or a second group, wherein the prognosis of subjects of the second group is worse than the prognosis of subjects of the first group, comprising the steps of: a) evaluating an amount of PODXL in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; b) comparing said sample value with a predetermined reference value; and if said sample value is higher than said reference value, c1) concluding that the subject belongs to the second group; and if said sample value is lower than or equal to said reference value, c2) concluding that the subject belongs to the first group.
Claims18
Method for determining whether a mammalian subject having a bladder cancer belongs to a first or a second group, wherein the prognosis of subjects of the second group is worse than the prognosis of subjects of the first group, comprising the steps of:
- a) evaluating an amount of PODXL in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount;
- b) comparing said sample value with a predetermined reference value;
- and
- if said sample value is higher than said reference value,
- c1) concluding that the subject belongs to the second group;
- and
- if said sample value is lower than or equal to said reference value,
- c2) concluding that the subject belongs to the first group.
Method of treatment of a subject having a bladder cancer, comprising the steps of:
- a) evaluating an amount of PODXL in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount;
- b) comparing said sample value with a predetermined reference value;
- and
- if said sample value is higher than said reference value,
- c) treating said subject with a first treatment regimen;
- and
- if said sample value is lower than or equal to said reference value,
- d) treating said subject with a second treatment regimen,
- wherein said first treatment regimen is more comprehensive than the second treatment regimen.
Method of treatment of a subject having a stage Ta or T1 bladder cancer, comprising the steps of:
- a) evaluating an amount of PODXL in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount;
- b) comparing said sample value with a predetermined reference value;
- and
- if said sample value is higher than said reference value,
- treating said subject with a treatment selected from the group consisting of chemotherapy, Bacillus Calmette-Guerin (BCG) treatment and primary cystectomy.
Method of treatment of a subject having an invasive bladder cancer, comprising the steps of:
- a) evaluating an amount of PODXL in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount;
- b) comparing said sample value with a predetermined reference value;
- and
- if said sample value is higher than said reference value,
- c) applying a treatment selected from the group consisting of chemotherapy, biological treatment and radiation therapy.
-14. (canceled)
Dependencies are inferred from the claim text.